Proliferative activity and diagnostic delay in oral cancer
✍ Scribed by Juan Seoane; Salvador Pita-Fernández; Iria Gómez; Inés Vazquez; José Luis López-Cedrún; Domingo De Agustin; Pablo Varela-Centelles
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 200 KB
- Volume
- 32
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background
Tumor stage may relate to the chronology of neoplasm growth and has been used as an outcome variable when studying diagnostic delay in oral cancer. However, tumor growth rate may act as a confounding factor.
Methods
We reviewed a total of 63 incident cases of oral cancer. The variables considered for the study included age, sex, smoking history, tumor site, TNM stage, Ki‐67 score, and diagnostic delay.
Results
Significant differences between survivors and exitus were found in terms of tumor stage at diagnosis (I–II vs III–IV), sex, and Ki‐67 scores. When the analysis was adjusted for tumor stage at diagnosis (I–II vs III–IV), proliferative activity resulted to be an independent prognostic factor for survival, whereas diagnostic delay did not influence survival.
Conclusion
These results seem to suggest that survival from oral cancer is affected more by the biology of the cancer (rapid tumor growth) than by diagnostic delay. © 2010 Wiley Periodicals, Inc. Head Neck, 2010
📜 SIMILAR VOLUMES
The proliferative activity of breast cancer has been analyzed in relation to the hormonal characteristics of the host and of the tumor for 199 patients. The analyses of labeling index frequency distributions of estrogen receptor positive (ER') and negative (ER-) cancers from premenopausal and postme
## Abstract ## Objectives/Hypothesis: The objective of this study was to examine the evidence for an association between patient and/or provider‐related diagnostic delay and late stage at diagnosis. ## Study Design: We identified all English language published studies worldwide and present a sum
Paraffin-embedded primary tumor specimens from 48 patients with breast cancer were examined for DNA ploidy, S-phase fraction (SPF), and concanavalin A (Con A) reactivity. The results were correlated with clinicopathological prognostic factors, including patients' age and menopausal status, stage of